▎Edited by the WuXi AppTec content team
According to incomplete statistics from Innovation Radar, last week (October 2 to October 8), the global health sectorA total of 25 financing events were disclosed, with a total amount exceeding 3 billion yuan.。According to the amount,Eight financings over 100 million yuan, the highest financing amount comes from the United StatesAI Drug Discovery PlatformTaiwan Iambic TherapeuticsThe $100 million financing was completed. According to the financing rounds, apart from the unknown rounds, there were 6 early-stage financings (before Series B) and 11 mid-to-late stage financings (Series B and onwards). A total of 7 companies in the biopharmaceutical field received financing, involving drug types including cancer immunotherapy, cell therapy, etc.。
#01
Obio, Sequoia and others are optimistic! Iambic Therapeutics completes $100 million Series B financing
Keywords: Artificial Intelligence
Latest Financing:$100 Million BRound
This Round Investment InstitutionsAscenta Capital, Abingworth, OrbiMed, Sequoia Capital, etc.
On October 3, Iambic Therapeutics announced the completion of a $100 million Series B financing round. Iambic Therapeutics is dedicated to leveraging an artificial intelligence (AI) drug discovery platform to develop new therapies. By combining physics and artificial intelligence, the platform can identify candidate therapeutic drugs with differentiated drug characteristics.The company has two clinical-stage drug candidates., highly selective and brain-penetrant HER2 inhibitor (IAM-H1) and selective dual CDK2/4 inhibitor (IAM-C1), can address unmet needs in the treatment of cell cycle-driven cancers. In addition, the company has developed methods such as NeuralPLexer and OrbNet to drive its discovery platform. It is reported that this round of financing will be used to advance the clinical development of the company’s drug candidates, expand its drug pipeline, and continue building its AI-driven drug discovery platform.
#02
Adlai NortyeListed on NASDAQ, Focus on Innovative Oncology Drug Development
Keywords: Tumor Drugs
Latest Financing: IPO
On September 29, Adlai Nortye Biopharma Co., Ltd.Listed on the NASDAQ stock market in the United States.Adlai Nortye is a global biopharmaceutical company at the clinical stage, focusing on the development of innovative oncology drugs, with research and development as well as clinical operation centers established in both China and the United States. According to the company, its product pipeline currently covers more than 10 anti-tumor drug candidates.Four drugs are in the clinical stage.Among them, AN2025 (buparlisib) has received the FDA's Fast Track designation and is expected to become a treatment for recurrent or metastaticHead and Neck Squamous Cell CarcinomaA potential "first-in-class" drug is currently undergoing global multi-center Phase 3 clinical trials; AN1004 (pelareorep) has also received Fast Track designation from the FDA. It is an intravenously injectable oncolytic virus therapy for the treatment of metastatic breast cancer, currently in the registrational trial stage.
#03
Shorla Secures $35 Million in Series B Funding to Develop Cancer Drugs
Keywords: Tumor drugs
Latest Financing:$35 Million Series B
This round of investment institutions:Enterprise Ireland、Kurma Partners、Seroba Life SciencesOctober 4Shorla Oncology (Shorla) announced the completion of its $35 million Series B financing.This funding will help accelerate the development of Shorla's oncology portfolio, advance its R&D projects, launch therapeutic solutions that address drug shortages, and improve the development and application of oncology drugs.The company is advancing a series of oncology treatment products aimed at filling significant gaps in patient care.Shorla Recently Announced Nelarabine InjectionApproved for marketing by the U.S. FDAShorla's goal is to continuously launch products that enhance treatment efficiency by providing clinicians with more convenient formulations and offering patients easier-to-use therapeutic options.
#04
Mogrify Completes $10 Million Series A Financing to Advance Development of Novel Cell Technologies and Therapies
Keywords：Stem Cell Therapy
Latest Financing:$10 Million Series A Round
This round of investment institutions:Abcam Plc、Ahren Innovation Capital、Astellas Venture Management、Parkwalk Advisors
On October 2, Mogrify announced an additional $10 million in Series A financing, bringing the total amount of this round to $46 million. Mogrify is a novel cell technology and therapy development company aimed at transforming the development of in vitro cell therapies and pioneering a new generation of in vivo reprogramming therapies for unmet clinical needs in immuno-oncology, ophthalmology, and other disease areas.The company has independently developed a cell reprogramming technology platform., systematically improving the efficiency of stem cell-derived reprogramming by directly converting mature cell types while bypassing the pluripotent stem cell state. It is reported that this round of financing will support the further advancement of Mogrify's in vivo reprogramming therapy pipeline.
#05
Orakl Oncology Completes €3 Million Financing to Advance AI-Driven Precision Cancer Drug Development
Keywords: Artificial Intelligence
Latest Financing: €3M Unknown Round
This round of investment institutions: HCVC, Speedinvest, Verve Ventures
On October 4, Orakl Oncology announced the completion of a €3 million financing round. With the help of its proprietary artificial intelligence (AI) drug discovery platform,Orakl Oncology focuses on the development of precision cancer therapies, with a particular emphasis on colorectal and pancreatic cancer.By integrating potential "best-in-class" biology, clinical, and molecular data on a large scale, the biotechnology platform assists oncologists in identifying relevant targets and delivering drugs more quickly and effectively. Additionally, Orakl Oncology's continuously expanding collection of avatars captures the complexity and heterogeneity of cancer across populations, aiding in the identification of new therapeutic targets and predictive biomarkers, thereby increasing the success rate of clinical trials. Reportedly, this round of financing will be used to launch the company’s dry and wet lab projects, recruit key team members, and advance related collaborative projects.
Readers, please star⭐Chuangjianhui to receive updates第一时间.
Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.
Copyright Statement: This article was compiled and edited by the content team of WuXi AppTec based on publicly available information. Individuals are welcome to share it on their social media platforms, but unauthorized reprints or reproductions by media or institutions in any form to other platforms are prohibited. For reprint authorization, please contact"Chuangjian Hui"Contact us via the WeChat Official Account comments.
More Data Content Recommended
